DEBRA Research supports the teams of Dr. Emanuel Rognoni and Dr. Matthew Caley at Queen Mary University of London to make their preclinical capabilities accessible to the wider EB research community ā including academic laboratories, biotech, and pharmaceutical companies. By enabling access to standardized, high-quality preclinical data, the preclinical EB CRO accelerates translational progress and strengthens regulatory readiness, ultimately helping to bring effective new therapies for EB closer to patients.
EB Trial site support
University Medical Center Groningen
We provide targeted support to establish a dedicated EB clinical trial site at the University Medical Center Groningen. This collaboration strengthens translational EB research infrastructure and expands clinical trial capacity in a region recognized for its expertise in the diagnosis and care of people living with EB. This site is now equipped to conduct both company-sponsored and investigator-initiated clinical trials and is positioned to contribute to emerging international EB initiatives, including the planned global EB registry.
We support the interdisciplinary team within the Department of Dermatology in close coordination with Stichting Vlinderkind and DEBRA Netherlands, key EB non-profit organizations in the country.
DEBRA Research advances EB therapies through in-house development and impact investments, supporting innovative programs from readthrough drugs to novel topical and ocular treatments.
